{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T21:24:12Z","timestamp":1777411452682,"version":"3.51.4"},"reference-count":50,"publisher":"e-Century Publishing Corporation","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/fxvh4425","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T04:40:59Z","timestamp":1740544859000},"page":"501-516","source":"Crossref","is-referenced-by-count":3,"title":["Dissecting the high-risk property of 1q gain\/amplification in patients with newly diagnosed multiple myeloma"],"prefix":"10.62347","volume":"15","author":[{"given":"Xinyue","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas - current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","unstructured":"Kumar SK and Rajkumar SV. The multiple myelomas - current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol 2018; 15: 409-421.","journal-title":"Nat Rev Clin Oncol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"de Donk NWCJ","year":"2021","unstructured":"van de Donk NWCJ, Pawlyn C and Yong KL. Multiple myeloma. Lancet 2021; 397: 410-427.","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1182\/blood.2020008733","article-title":"How I treat high-risk multiple myeloma","volume":"139","author":"Zamagni","year":"2022","unstructured":"Zamagni E, Barbato S and Cavo M. How I treat high-risk multiple myeloma. Blood 2022; 139: 2889-2903.","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41408-022-00638-0","article-title":"Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis","volume":"12","author":"Atrash","year":"2022","unstructured":"Atrash S, Flahavan EM, Xu T, Ma E, Karve S, Hong WJ, Jirau-Lucca G, Nixon M and Ailawadhi S. Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis. Blood Cancer J 2022; 12: 46.","journal-title":"Blood Cancer J"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1038\/s41375-020-01096-y","article-title":"Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial","volume":"35","author":"Croft","year":"2021","unstructured":"Croft J, Ellis S, Sherborne AL, Sharp K, Price A, Jenner MW, Drayson MT, Owen RG, Chown S, Lindsay J, Karunanithi K, Hunter H, Gregory WM, Davies FE, Morgan GJ, Cook G, Atanesyan L, Savola S, Cairns DA, Jackson G, Houlston RS and Kaiser MF. Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. Leukemia 2021; 35: 2043-2053.","journal-title":"Leukemia"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Jin F, Gao G, Dong Y, Li C, Huang W, Zhang L, Zhu Q, Yuan R, Xu L, Xu Y, Xu Q, Kumar SK and Dai Y. A multi-center epidemiological and prognostic analysis of cytogenetic abnormalities in a cohort of 1015 Chinese patients with newly-diagnosed multiple myeloma. Blood 2019; 134; 3094.","DOI":"10.1182\/blood-2019-132076"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1182\/bloodadvances.2019001425","article-title":"Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents","volume":"4","author":"Giri","year":"2020","unstructured":"Giri S, Huntington SF, Wang R, Zeidan AM, Podoltsev N, Gore SD, Ma X, Gross CP, Davidoff AJ and Neparidze N. Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. Blood Adv 2020; 4: 2245-2253.","journal-title":"Blood Adv"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-021-00474-8","article-title":"Chromosome 1q21 abnormalities in multiple myeloma","volume":"11","author":"TM","year":"2021","unstructured":"Schmidt TM, Fonseca R and Usmani SZ. Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer J 2021; 11: 83.","journal-title":"Blood Cancer J"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A and Morgan G. A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia 2019; 33: 159-170.","journal-title":"Leukemia"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project","volume":"40","author":"D&#x2019","year":"2022","unstructured":"D’Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, Zamagni E, Mateos MV, Dall’Olio D, van de Donk NWCJ, Jackson G, Rocchi S, Salwender H, Bladé Creixenti J, van der Holt B, Castellani G, Bonello F, Capra A, Mai EK, Dürig J, Gay F, Zweegman S, Cavo M, Kaiser MF, Goldschmidt H, Hernández Rivas JM, Larocca A, Cook G, San-Miguel JF, Boccadoro M and Sonneveld P. Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol 2022; 40: 3406-3418.","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41408-022-00611-x","article-title":"A simple additive staging system for newly diagnosed multiple myeloma","volume":"12","author":"Abdallah","year":"2022","unstructured":"Abdallah NH, Binder M, Rajkumar SV, Greipp PT, Kapoor P, Dispenzieri A, Gertz MA, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder AL, Hobbs MA, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui MA, Kyle RA, Bergsagel PL, Fonseca R, Ketterling RP and Kumar SK. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J 2022; 12: 21.","journal-title":"Blood Cancer J"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1182\/bloodadvances.2020002218","article-title":"Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities","volume":"4","author":"Abdallah","year":"2020","unstructured":"Abdallah N, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder A, Hobbs M, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui M, Lust J, Kyle RA, Bergsagel L, Ketterling R, Rajkumar SV and Kumar SK. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Adv 2020; 4: 3509-3519.","journal-title":"Blood Adv"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Corre J, Munshi NC and Avet-Loiseau H. Risk factors in multiple myeloma: is it time for a revision? Blood 2021; 137: 16-19.","DOI":"10.1182\/blood.2019004309"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1182\/blood-2010-12-328252","article-title":"Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with total therapy 3","volume":"118","author":"JD Jr","year":"2011","unstructured":"Shaughnessy JD Jr, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, Tian E, Hanamura I, van Rhee F, Anaissie E, Epstein J, Nair B, Stephens O, Williams R, Waheed S, Alsayed Y, Crowley J and Barlogie B. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with total therapy 3. Blood 2011; 118: 3512-3524.","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-019-0254-0","article-title":"Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone","volume":"9","author":"Schmidt","year":"2019","unstructured":"Schmidt TM, Barwick BG, Joseph N, Heffner LT, Hofmeister CC, Bernal L, Dhodapkar MV, Gupta VA, Jaye DL, Wu J, Goyal S, Chen Z, Boise LH, Lonial S, Nooka AK and Kaufman JL. Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer J 2019; 9: 94.","journal-title":"Blood Cancer J"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41408-024-00985-0","article-title":"Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review","volume":"14","author":"Neupane","year":"2024","unstructured":"Neupane K, Fortuna GG, Dahal R, Schmidt T, Fonseca R, Chakraborty R, Koehn KA, Mohan M, Mian H, Costa LJ, Sborov D and Mohyuddin GR. Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. Blood Cancer J 2024; 14: 20.","journal-title":"Blood Cancer J"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41408-023-00973-w","article-title":"Outcomes of patients with multiple myeloma and 1q gain\/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience","volume":"14","author":"Pasvolsky","year":"2024","unstructured":"Pasvolsky O, Ghanem S, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Khan HN, Kebriaei P, Lee HC, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE and Qazilbash MH. Outcomes of patients with multiple myeloma and 1q gain\/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience. Blood Cancer J 2024; 14: 4.","journal-title":"Blood Cancer J"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/jha2.47","article-title":"Use of daratumumab in high risk multiple myeloma: a meta-analysis","volume":"1","author":"Premkumar","year":"2020","unstructured":"Premkumar V, Pan S, Lentzsch S and Bhutani D. Use of daratumumab in high risk multiple myeloma: a meta-analysis. EJHaem 2020; 1: 267-271.","journal-title":"EJHaem"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/bjh.17499","article-title":"Subgroup analysis of ICARIA-MM study in relapsed\/refractory multiple myeloma patients with high-risk cytogenetics","volume":"194","author":"SJ","year":"2021","unstructured":"Harrison SJ, Perrot A, Alegre A, Simpson D, Wang MC, Spencer A, Delimpasi S, Hulin C, Sunami K, Facon T, Vlummens P, Yong K, Campana F, Inchauspé M, Macé S, Risse ML, van de Velde H and Richardson P. Subgroup analysis of ICARIA-MM study in relapsed\/refractory multiple myeloma patients with high-risk cytogenetics. Br J Haematol 2021; 194: 120-131.","journal-title":"Br J Haematol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.6004\/jnccn.2020.7673","article-title":"Defining and managing high-risk multiple myeloma: current concepts","volume":"18","author":"Costa","year":"2020","unstructured":"Costa LJ and Usmani SZ. Defining and managing high-risk multiple myeloma: current concepts. J Natl Compr Canc Netw 2020; 18: 1730-1737.","journal-title":"J Natl Compr Canc Netw"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1200\/JCO.19.02515","article-title":"Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma","volume":"38","author":"Joseph","year":"2020","unstructured":"Joseph NS, Kaufman JL, Dhodapkar MV, Hofmeister CC, Almaula DK, Heffner LT, Gupta VA, Boise LH, Lonial S and Nooka AK. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol 2020; 38: 1928-1937.","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","unstructured":"Paiva B, Puig N, Cedena MT, Rosiñol L, Cordón L, Vidriales MB, Burgos L, Flores-Montero J, Sanoja-Flores L, Lopez-Anglada L, Maldonado R, de la Cruz J, Gutierrez NC, Calasanz MJ, Martin-Ramos ML, Garcia-Sanz R, Martinez-Lopez J, Oriol A, Blanchard MJ, Rios R, Martin J, Martinez-Martinez R, Sureda A, Hernandez MT, de la Rubia J, Krsnik I, Moraleda JM, Palomera L, Bargay J, Van Dongen JJM, Orfao A, Mateos MV, Blade J, San-Miguel JF and Lahuerta JJ; GEM (Grupo Español de Mieloma)\/PETHEMA (Programa Para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol 2020; 38: 784-792.","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/ajh.26774","article-title":"Proposed risk-scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma","volume":"98","author":"Yang","year":"2023","unstructured":"Yang P, Chen H, Liang X, Xu W, Yu S, Huang W, Yi X, Guo Q, Tian M, Yue T, Li M, Zhang Y, Zhang M, Yan Y, Hu Z, Kumar SK, Zhou F, Dai Y and Jin F. Proposed risk-scoring model for estimating the prognostic impact of 1q gain in patients with newly diagnosed multiple myeloma. Am J Hematol 2023; 98: 251-263.","journal-title":"Am J Hematol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV and Moreau P. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 2015; 33: 2863-2869.","journal-title":"J Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Yang P, Xu W, Liang X, Yu S, Yi X, Liu M, Tian M, Yue T, Zhang Y, Yan Y, Hu Z, Guo Q, Zhang N, Wang J, Sun X, Hu R, Kumar SK, Dai Y and Jin F. Dynamic monitoring of minimal residual disease in newly-diagnosed multiple myeloma. Am J Hematol 2023; 98: E61-E64.","DOI":"10.1002\/ajh.26810"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","article-title":"International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials","volume":"35","author":"Costa","year":"2021","unstructured":"Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell RF, Holstein SA, Shi Q, Omel J, Callander NS, Chng WJ, Hungria V, Maiolino A, Stadtmauer E, Giralt S, Pasquini M, Jakubowiak AJ, Morgan GJ, Krishnan A, Jackson GH, Mohty M, Mateos MV, Dimopoulos MA, Facon T, Spencer A, Miguel JS, Hari P, Usmani SZ, Manier S, McCarthy P, Kumar S, Gay F and Paiva B. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia 2021; 35: 18-30.","journal-title":"Leukemia"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS and Avet-Loiseau H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17: e328-e346.","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"SV","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC and San Miguel J; International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011; 117: 4691-4695.","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","article-title":"Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders","volume":"97","author":"FM","year":"2012","unstructured":"Ross FM, Avet-Loiseau H, Ameye G, Gutiérrez NC, Liebisch P, O’Connor S, Dalva K, Fabris S, Testi AM, Jarosova M, Hodkinson C, Collin A, Kerndrup G, Kuglik P, Ladon D, Bernasconi P, Maes B, Zemanova Z, Michalova K, Michau L, Neben K, Hermansen NE, Rack K, Rocci A, Protheroe R, Chiecchio L, Poirel HA, Sonneveld P, Nyegaard M and Johnsen HE; European Myeloma Network. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica 2012; 97: 1272-1277.","journal-title":"Haematologica"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Gao L, Liu Y, Li Y, Feng L, Wang Z, Wen L, Wang F, Huang X, Lu J and Lai Y. The importance of FISH signal cut-off value and copy number variation for 1q21 in newly diagnosed multiple myeloma: is it underestimated? Clin Lymphoma Myeloma Leuk 2022; 22: 535-544.","DOI":"10.1016\/j.clml.2022.01.013"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Corre J, Montes L, Martin E, Perrot A, Caillot D, Leleu X, Belhadj K, Facon T, Hulin C, Mohty M, Fontan J, Macro M, Brechignac S, Jaccard A, Stoppa AM, Orsini-Piocelle F, Adiko D, Voillat L, Keddar F, Barry M, Demarquette H, Certain MN, Plantier I, Roussel M, Hébraud B, Filleron T, Attal M and Avet-Loiseau H. Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk. Haematologica 2020; 105: e480-e483.","DOI":"10.3324\/haematol.2019.236588"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.3324\/haematol.2021.278888","article-title":"Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients","volume":"106","author":"Weinhold","year":"2021","unstructured":"Weinhold N, Salwender HJ, Cairns DA, Raab MS, Waldron G, Blau IW, Bertsch U, Hielscher T, Morgan GJ, Jauch A, Davies FE, Hänel M, Cook G, Scheid C, Houlston R, Goldschmidt H, Jackson G and Kaiser MF. Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients. Haematologica 2021; 106: 2754-2758.","journal-title":"Haematologica"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/ejh.12255","article-title":"Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents","volume":"92","author":"Zagouri","year":"2014","unstructured":"Zagouri F, Kastritis E, Symeonidis AS, Giannakoulas N, Katodritou E, Delimpasi S, Repousis P, Terpos E and Dimopoulos MA; Greek Myeloma Study Group. Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents. Eur J Haematol 2014; 92: 308-312.","journal-title":"Eur J Haematol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41375-020-01060-w","article-title":"Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN)","volume":"35","author":"Liu","year":"2021","unstructured":"Liu J, Hu X, Jia Y, Lu J, Lee JH, Kim K, Chen W, Liu A, Liu Y, Chen Q, Zhang C, Suh C, Kim MK, Zhou F, Chng WJ, Kumar SK, Durie B, Hou J, Fu W and Du J. Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN). Leukemia 2021; 35: 1797-1802.","journal-title":"Leukemia"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/ajh.26391","article-title":"Prognostic significance of acquired 1q22 gain in multiple myeloma","volume":"97","author":"Audil","year":"2022","unstructured":"Audil HY, Cook JM, Greipp PT, Kapoor P, Baughn LB, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Muchtar E, Siddiqui M, Gonsalves WI, Hwa YL, Leung N, Lin Y, Kourelis TV, Warsame R, Kyle RA, Ketterling RP, Rajkumar SV and Kumar SK. Prognostic significance of acquired 1q22 gain in multiple myeloma. Am J Hematol 2022; 97: 52-59.","journal-title":"Am J Hematol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1038\/sj.leu.2404403","article-title":"Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma","volume":"20","author":"Fonseca","year":"2006","unstructured":"Fonseca R, Van Wier SA, Chng WJ, Ketterling R, Lacy MQ, Dispenzieri A, Bergsagel PL, Rajkumar SV, Greipp PR, Litzow MR, Price-Troska T, Henderson KJ, Ahmann GJ and Gertz MA. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 2006; 20: 2034-2040.","journal-title":"Leukemia"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"WJ","year":"2014","unstructured":"Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG and Avet-Loiseau H; International Myeloma Working Group. IMWG consensus on risk stratification in multiple myeloma. Leukemia 2014; 28: 269-277.","journal-title":"Leukemia"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/leu.2011.204","article-title":"A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial","volume":"26","author":"KD","year":"2012","unstructured":"Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ, Bell SE, Child JA, Jackson GH, Davies FE and Morgan GJ; NCRI Haematology Oncology Studies Group. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia 2012; 26: 349-355.","journal-title":"Leukemia"},{"key":"ref38","unstructured":"Minguela A, Vasco-Mogorrón MA, Campillo JA, Cabañas V, Remigia MJ, Berenguer M, García-Garay MC, Blanquer M, Cava C, Galian JA, Gimeno L, Soto-Ramírez MF, Martínez-Hernández MD, de la Rubia J, Teruel AI, Muro M and Periago A. Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment. Am J Cancer Res 2021; 11: 4438-4454."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3390\/cancers13020256","article-title":"Gain\/amplification of chromosome arm 1q21 in multiple myeloma","volume":"13","author":"Hanamura","year":"2021","unstructured":"Hanamura I. Gain\/amplification of chromosome arm 1q21 in multiple myeloma. Cancers (Basel) 2021; 13: 256.","journal-title":"Cancers (Basel)"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.1182\/blood-2019-130092","article-title":"0 and autologous stem cell transplantation for patients with newly diagnosed multiple myeloma","volume":"134","author":"Garifullin","year":"2019","unstructured":"Garifullin A, Voloshin S, Shuvaev V, Martynkevich I, Kleina E, Chechetkin A, Bessmeltcev S, Kuzyaeva A, Sсhmidt A, Kuvshinov A and Pavlova I. Significance of modified risk stratification mSmart 3.0 and autologous stem cell transplantation for patients with newly diagnosed multiple myeloma. Blood 2019; 134: 5593.","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Binder M, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Hayman SR, Hwa YL, Zeldenrust SR, Lust JA, Russell SJ, Leung N, Kapoor P, Go RS, Gonsalves WI, Kyle RA and Kumar SK. Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma. Blood Cancer J 2017; 7: e600.","DOI":"10.1038\/bcj.2017.83"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.bbmt.2019.12.726","article-title":"Outcome of multiple myeloma with chromosome 1q gain and 1p deletion after autologous hematopoietic stem cell transplantation: propensity score matched analysis","volume":"26","author":"Varma","year":"2020","unstructured":"Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE and Qazilbash MH. Outcome of multiple myeloma with chromosome 1q gain and 1p deletion after autologous hematopoietic stem cell transplantation: propensity score matched analysis. Biol Blood Marrow Transplant 2020; 26: 665-671.","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1182\/blood.2022017863","article-title":"Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor","volume":"141","author":"Schavgoulidze","year":"2023","unstructured":"Schavgoulidze A, Talbot A, Perrot A, Cazaubiel T, Leleu X, Manier S, Buisson L, Mahéo S, Do Souto Ferreira L, Pavageau L, Hulin C, Marolleau JP, Voillat L, Belhadj K, Divoux M, Slama B, Brechignac S, Macro M, Stoppa AM, Sanhes L, Orsini-Piocelle F, Fontan J, Chretien ML, Demarquette H, Mohty M, Avet-Loiseau H and Corre J. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor. Blood 2023; 141: 1308-1315.","journal-title":"Blood"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1200\/JCO.18.00776","article-title":"Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma","volume":"37","author":"Perrot","year":"2019","unstructured":"Perrot A, Lauwers-Cances V, Tournay E, Hulin C, Chretien ML, Royer B, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Fontan J, Voillat L, Demarquette H, Collet P, Rodon P, Sohn C, Lifermann F, Orsini-Piocelle F, Richez V, Mohty M, Macro M, Minvielle S, Moreau P, Leleu X, Facon T, Attal M, Avet-Loiseau H and Corre J. Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma. J Clin Oncol 2019; 37: 1657-1665.","journal-title":"J Clin Oncol"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"D’Agostino M, Ruggeri M, Aquino S, Giuliani N, Arigoni M, Gentile M, Olivero M, Vincelli ID, Capra A, Mussatto C, Ledda A, Tacchetti P, Musolino C, Cellini C, Patriarca F, Ballanti S, Calogero R, Musto P, Boccadoro M and Gay F. Impact of gain and amplification of 1q in newly diagnosed multiple myeloma patients receiving carfilzomib-based treatment in the forte trial. Blood 2020; 136: 38-40.","DOI":"10.1182\/blood-2020-137060"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1001\/jamaoncol.2020.4338","article-title":"Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic review and meta-analysis","volume":"6","author":"Giri","year":"2020","unstructured":"Giri S, Grimshaw A, Bal S, Godby K, Kharel P, Djulbegovic B, Dimopoulos MA, Facon T, Usmani SZ, Mateos MV and Costa LJ. Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic review and meta-analysis. JAMA Oncol 2020; 6: 1759-1765.","journal-title":"JAMA Oncol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"LJ","year":"2022","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, Silbermann R, Dhakal B, Bal S, Giri S, D’Souza A, Hall A, Hardwick P, Omel J, Cornell RF, Hari P and Callander NS. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J Clin Oncol 2022; 40: 2901-2912.","journal-title":"J Clin Oncol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood.2020006731","article-title":"Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma","volume":"137","author":"Goicoechea","year":"2021","unstructured":"Goicoechea I, Puig N, Cedena MT, Burgos L, Cordón L, Vidriales MB, Flores-Montero J, Gutierrez NC, Calasanz MJ, Ramos MM, Lara-Astiaso D, Vilas-Zornoza A, Alignani D, Rodriguez I, Sarvide S, Alameda D, Garcés JJ, Rodriguez S, Fresquet V, Celay J, Garcia-Sanz R, Martinez-Lopez J, Oriol A, Rios R, Martin-Sanchez J, Martinez-Martinez R, Sarra J, Hernandez MT, de la Rubia J, Krsnik I, Moraleda JM, Palomera L, Bargay J, Martinez-Climent JA, Orfao A, Rosiñol L, Mateos MV, Lahuerta JJ, Blade J, San Miguel J and Paiva B. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. Blood 2021; 137: 49-60.","journal-title":"Blood"},{"key":"ref49","unstructured":"Avet-Loiseau H, Lauwers-Cances V, Corre J, Moreau P, Attal M and Munshi N. Minimal residual disease in multiple myeloma: final analysis of the IFM2009 trial. Blood 2017; 130: 435."}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/2\/ajcr0160493.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:57:27Z","timestamp":1766023047000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/2\/ajcr0160493.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/fxvh4425","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}